[{"address1": "Avinguda de la Generalitat, 152", "address2": "Parc empresarial Can Sant Joan Sant Cugat del Valles", "city": "Barcelona", "zip": "08174", "country": "Spain", "phone": "34 935 712 200", "fax": "34 938 008 000", "website": "https://www.grifols.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.", "fullTimeEmployees": 23505, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas H. Glanzmann", "age": 65, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 2089164, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jose Ignacio  Abia Buenache", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alfredo Arroyo Guerra", "age": 65, "title": "CFO & VP", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lluis Pons Gomez", "age": 40, "title": "Senior Vice President of Strategy & COO Office", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nuria Pascual Lape\u00f1a", "age": 59, "title": "VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Ian Bell", "age": 69, "title": "Chief Corporate Development, Legal & Data Protection Officer", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Teresa-Rion\u00e9 Llano", "age": 58, "title": "Chief Communications Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Camille  Alpi", "age": 42, "title": "Chief Human Resources & Talent Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vicente  Blanquer Torre", "age": 62, "title": "Chief Quality Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sergio Roura Adell", "age": 55, "title": "President of Commercial Tech Support", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 8, "overallRisk": 3, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.89, "open": 6.89, "dayLow": 6.755, "dayHigh": 6.935, "regularMarketPreviousClose": 6.89, "regularMarketOpen": 6.89, "regularMarketDayLow": 6.755, "regularMarketDayHigh": 6.935, "exDividendDate": 1622678400, "fiveYearAvgDividendYield": 2.4, "beta": 0.699, "trailingPE": 26.576923, "forwardPE": 5.855932, "volume": 477954, "regularMarketVolume": 477954, "averageVolume": 1462206, "averageVolume10days": 1177590, "averageDailyVolume10Day": 1177590, "bid": 6.9, "ask": 6.96, "bidSize": 300, "askSize": 100, "marketCap": 5609959424, "fiftyTwoWeekLow": 5.3, "fiftyTwoWeekHigh": 12.15, "priceToSalesTrailing12Months": 0.8237047, "fiftyDayAverage": 7.4158, "twoHundredDayAverage": 7.92155, "currency": "USD", "enterpriseValue": 16644131840, "profitMargins": 0.024330001, "floatShares": 546972376, "sharesOutstanding": 257444000, "sharesShort": 8100706, "sharesShortPriorMonth": 8777976, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0111, "heldPercentInstitutions": 0.53601, "shortRatio": 3.36, "impliedSharesOutstanding": 811860992, "bookValue": 8.229, "priceToBook": 0.83971316, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.611, "netIncomeToCommon": 165672992, "trailingEps": 0.26, "forwardEps": 1.18, "pegRatio": 0.12, "lastSplitFactor": "2:1", "lastSplitDate": 1451865600, "enterpriseToRevenue": 2.444, "enterpriseToEbitda": 14.975, "52WeekChange": -0.31854045, "SandP52WeekChange": 0.24822903, "lastDividendValue": 0.456, "lastDividendDate": 1622678400, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GRFS", "underlyingSymbol": "GRFS", "shortName": "Grifols, S.A.", "longName": "Grifols, S.A.", "firstTradeDateEpochUtc": 1307021400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ff4804c3-7e74-32e2-af9a-01ef612b3fc8", "messageBoardId": "finmb_734865", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.91, "targetHighPrice": 12.08, "targetLowPrice": 11.2, "targetMeanPrice": 11.64, "targetMedianPrice": 11.64, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 2259549952, "totalCashPerShare": 3.325, "ebitda": 1111435008, "totalDebt": 11504876544, "quickRatio": 0.777, "currentRatio": 1.682, "totalRevenue": 6810643968, "debtToEquity": 138.692, "revenuePerShare": 4.7015, "returnOnAssets": 0.02473, "returnOnEquity": 0.028169999, "freeCashflow": 159467632, "operatingCashflow": 376582016, "earningsGrowth": -0.667, "revenueGrowth": 0.093, "grossMargins": 0.38764, "ebitdaMargins": 0.16319, "operatingMargins": 0.16194001, "financialCurrency": "EUR", "trailingPegRatio": 0.2245, "__fetch_time": "2024-08-15"}]